Urs Albert Meyer

Title: Urs Albert Meyer: Innovator in Pharmacogenomics

Introduction

Urs Albert Meyer is a notable inventor based in Oberwil, Switzerland. He has made significant contributions to the field of pharmacogenomics, particularly in the detection of poor metabolizers of drugs. With a total of 3 patents to his name, his work has implications for personalized medicine and drug efficacy.

Latest Patents

Meyer’s latest patents include innovative methods for detecting poor metabolizers of drugs using PCR technology. One of his patents focuses on primers targeted to the NAT2 gene, which aids in identifying individuals who metabolize drugs poorly. This method involves amplifying a gene coding for an enzyme responsible for drug metabolism, thereby distinguishing it from closely related pseudogenes. Additionally, he has developed primers targeted to the CYP2D6 gene, which also assists in detecting poor metabolizers. Both patents emphasize the importance of amplifying different allelic forms of these genes and detecting the resulting products.

Career Highlights

Throughout his career, Urs Albert Meyer has worked with prominent companies, including Hoffmann-La Roche Inc. His expertise in pharmacogenomics has positioned him as a key figure in the development of diagnostic tools that enhance drug safety and efficacy.

Collaborations

Meyer has collaborated with notable professionals in his field, including Heinz Biber and Urs B Meyer. These collaborations have contributed to the advancement of research in pharmacogenomics and the development of innovative solutions for drug metabolism issues.

Conclusion

Urs Albert Meyer is a distinguished inventor whose work in pharmacogenomics has paved the way for advancements in personalized medicine. His patents reflect a commitment to improving drug safety and efficacy through innovative detection methods.